Divisions of Pathology and Clinical Laboratories, Japan; Divisions of Pharmaco-Proteomics, Japan; Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Graduate School of Biomedical Sciences, Hiroshima University, Hiroshima, Japan.
Divisions of Pathology and Clinical Laboratories, Japan.
Ann Oncol. 2012 Dec;23(12):3129-3137. doi: 10.1093/annonc/mds147. Epub 2012 Jun 13.
Insulin-like growth factor-1 receptor (IGF-1R), epidermal growth factor receptor (EGFR), human epidermal growth factor receptor-type 2 (HER2), and c-Met are members of the receptor tyrosine kinases (RTKs). The associations between the RTK status [protein expression and gene copy number (GCN)] and patient characteristics and between the RTK status and prognosis remain undetermined.
The study included 140 patients who underwent surgery for thymic tumors. Protein expression was evaluated by immunohistochemistry (IHC) and GCN was evaluated by bright-field in situ hybridization (BISH). The correlations between the RTK status and clinicopathological findings were examined.
IGF-1R protein was frequently detected in thymic carcinoma (83.8%) and EGFR in thymic tumors (91.4%). Thirty-six and 39 tumors were BISH high for IGF-1R and EGFR, respectively: 28 and 25 exhibited high polysomy; 8 and 14 exhibited gene amplification. No tumor was positive for HER2 or c-Met by IHC and BISH. Multivariate analysis revealed that IGF-1R gene amplification (P = 0.027), thymic carcinoma histology, and higher tumor stage were significantly correlated with an adverse prognosis.
Thymic epithelial tumors frequently express IGF-1R and/or EGFR proteins. IGF-1R gene amplification is suggested to define an unfavorable subset for thymic epithelial tumors.
胰岛素样生长因子-1 受体(IGF-1R)、表皮生长因子受体(EGFR)、人表皮生长因子受体 2(HER2)和 c-Met 是受体酪氨酸激酶(RTK)的成员。RTK 状态(蛋白表达和基因拷贝数(GCN))与患者特征之间的关联以及 RTK 状态与预后之间的关联尚未确定。
本研究纳入了 140 名接受胸腺肿瘤手术的患者。通过免疫组织化学(IHC)评估蛋白表达,通过荧光原位杂交(BISH)评估 GCN。检查了 RTK 状态与临床病理发现之间的相关性。
IGF-1R 蛋白在胸腺癌中频繁检测到(83.8%),在胸腺瘤中检测到 EGFR(91.4%)。36 个和 39 个肿瘤的 IGF-1R 和 EGFR 分别为 BISH 高:28 个和 25 个表现为高多倍体;8 个和 14 个表现为基因扩增。免疫组织化学和 BISH 均未检测到 HER2 或 c-Met 阳性肿瘤。多变量分析显示,IGF-1R 基因扩增(P=0.027)、胸腺癌组织学和更高的肿瘤分期与不良预后显著相关。
胸腺瘤上皮肿瘤常表达 IGF-1R 和/或 EGFR 蛋白。IGF-1R 基因扩增可能提示胸腺瘤上皮肿瘤的不良亚群。